1. HBW Insight
  2. >>Health
  3. >>Business
  4. >>Deals

Perrigo Continues Overhaul Adding HRA Pharma, Boosts Chances For OTC Oral Contraceptive In US

 
• By Malcolm Spicer

HRA’s approval for pharmacy sales of a daily oral contraceptive the UK and its ongoing work on an NDA to propose making another progestin-only contraceptive ingredient available OTC in the US stand out as additions to Perrigo’s business with the most substantial revenue impacts.

• Source: Alamy

Pharma industry weight behind making daily oral contraceptives available OTC in the US gains substantial heft with Perrigo Company PLC’s planned acquisition of French firm HRA Pharma, which recently received UK approval for nonprescription sales of a daily-use progestin-only contraceptive.

With its acquisition of HRA, officially identified in France as Héra SAS, for €1.8bn ($2.1bn) in a cash deal announced...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

AESGP Annual Meeting: Consumer Health Sector Still Safe Bet For Investors

 
• By David Ridley

A healthy diversity of different types of players and plenty of space for scaling up are among the reasons that investors remain interested in the consumer health sector, according to investment bankers speaking at the recent AESGP Annual Meeting.

Germany’s PharmaSGP To Be Taken Private

 
• By Tom Gallen

Consumer health player PharmaSGP will be taken private by its biggest shareholder, FUTRUE.

Alliance Pharma’s New Owners Will Instill ‘More Consumer-Oriented Mindset’

 
• By Tom Gallen

Private equity firms now in control of Alliance Pharma weighing úp plan to offload Rx business to help finance strategy to drive up sales and growth.

C&D Taps Hand Sanitizer Category With Touchland

 
• By Malcolm Spicer

Deal totaling as much as $880m extends C&D into additional product category with a brand it says is the fastest growing in the US hand sanitizer category and No. 2 brand in the category overall.

More from Business

TheraBreath ‘Guarantee Better’ Claim Serious, Not Puffery With Founder Prominent In Advertising

 
• By Malcolm Spicer

Challenged advertising, which appeared in a TV commercial, in-store displays and advertising on social media, included express claims “It’s a better mouthwash. I guarantee it.” and “I guarantee it. – ‘Dr. Harold Katz.’”

US Consumer Health Sector Vigilant To Avoid Stumbling On Trump’s Tariff Twists And Turns

 
• By Malcolm Spicer

In remarks at recent investor conference reflecting comments from across the US consumer health sector, Kenvue chief Thibaut Mongon says, “I'm going to state the obvious. The environment is very fluid.”

AESGP Annual Meeting: Consumer Health Sector Still Safe Bet For Investors

 
• By David Ridley

A healthy diversity of different types of players and plenty of space for scaling up are among the reasons that investors remain interested in the consumer health sector, according to investment bankers speaking at the recent AESGP Annual Meeting.